Scientists in the US have found a potential therapeutic treatment for SARS-CoV-2, the virus that causes Covid-19, and other coronaviruses.
Pathogenic coronaviruses are a major threat to global public health, as shown by the SARS-CoV, MERS-CoV, and the newly emerged SARS-CoV-2.
The study, published in the journal Science Translational Medicine, has found that small molecule protease inhibitors show potency against human coronaviruses.
These coronavirus 3C-like proteases, known as 3CLpro, are strong therapeutic targets because they play vital roles in coronavirus replication, the researchers said.
"Vaccine developments and treatments are the biggest targets in Covid-19 research, and treatment is really key," said Kyeong-Ok Chang, a professor at Kansas State University in the US.
"This paper describes protease inhibitors targeting coronavirus 3CLpro, which is a well-known therapeutic target," Chang said.
The study demonstrates that this series of optimised coronavirus 3CLpro inhibitors blocked replication of the human coronaviruses MERS-CoV and SARS-CoV-2 in cultured cells and in a mouse model for MERS, the researchers said.
These findings suggest that this series of compounds should be investigated further as a potential therapeutic for human coronavirus infection, they said.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)